Alignment Healthcare, Inc. $ALHC Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its holdings in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) by 442.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,387 shares of the company’s stock after acquiring an additional 72,900 shares during the period. Quantinno Capital Management LP’s holdings in Alignment Healthcare were worth $1,575,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ALHC. Vanguard Group Inc. boosted its holdings in shares of Alignment Healthcare by 10.9% during the 4th quarter. Vanguard Group Inc. now owns 15,492,802 shares of the company’s stock worth $305,983,000 after purchasing an additional 1,524,218 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Alignment Healthcare by 26.9% in the fourth quarter. Wellington Management Group LLP now owns 14,070,893 shares of the company’s stock valued at $277,900,000 after purchasing an additional 2,981,166 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Alignment Healthcare by 0.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock valued at $249,715,000 after purchasing an additional 79,268 shares during the last quarter. Invesco Ltd. lifted its position in Alignment Healthcare by 38.9% during the fourth quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after buying an additional 1,735,962 shares in the last quarter. Finally, 8 Knots Management LLC lifted its position in Alignment Healthcare by 6.4% during the second quarter. 8 Knots Management LLC now owns 5,015,881 shares of the company’s stock worth $70,222,000 after buying an additional 300,409 shares in the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Insider Buying and Selling at Alignment Healthcare

In other news, CEO John E. Kao sold 298,000 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $13.88, for a total transaction of $4,136,240.00. Following the sale, the chief executive officer owned 790,766 shares of the company’s stock, valued at approximately $10,975,832.08. This represents a 27.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Hyong Kim sold 35,951 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $19.86, for a total transaction of $713,986.86. Following the completion of the transaction, the insider directly owned 331,750 shares of the company’s stock, valued at approximately $6,588,555. The trade was a 9.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,039,951 shares of company stock valued at $19,079,987. Corporate insiders own 5.20% of the company’s stock.

Alignment Healthcare Trading Up 2.4%

Shares of NASDAQ ALHC opened at $13.52 on Thursday. The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $2.80 billion, a PE ratio of 71.16 and a beta of 1.10. Alignment Healthcare, Inc. has a twelve month low of $13.05 and a twelve month high of $25.12. The stock has a fifty day simple moving average of $19.49 and a 200-day simple moving average of $19.26.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Thursday, July 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.04. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%.The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the prior year, the company earned $0.07 EPS. Alignment Healthcare’s revenue was up 31.6% on a year-over-year basis. On average, equities analysts forecast that Alignment Healthcare, Inc. will post 0.17 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on ALHC shares. Wolfe Research began coverage on Alignment Healthcare in a research note on Friday, April 17th. They set an “outperform” rating and a $24.00 price objective on the stock. Barclays cut their target price on Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 26th. TD Cowen reiterated a “buy” rating on shares of Alignment Healthcare in a report on Monday, August 3rd. Wall Street Zen lowered Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Zacks Research cut Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.60.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: An analyst upgrade argued that Alignment’s valuation drawdown has created potential upside. The company’s second-quarter performance included 31% membership growth, a record-low medical benefits ratio, 48% adjusted EBITDA growth and increased full-year guidance. Alignment Healthcare: The Drawdown I Told You To Wait For Has Arrived
• Positive Sentiment: Recent quarterly results remain a fundamental support: Alignment reported earnings of $0.17 per share versus the $0.13 consensus estimate, while revenue rose 31.6% year over year to $1.34 billion. Analysts maintain a “Moderate Buy” consensus, with an average price target of $23.60.
• Neutral Sentiment: Institutional ownership is substantial at 86.19%, and several major investors recently increased or initiated positions. However, this support has not prevented the shares from trading near recent lows.
• Negative Sentiment: Multiple law firms, including Kaplan Fox, Frank R. Cruz and Pomerantz, announced investigations into possible securities-law violations and potential investor claims. The reports reference a 16% share-price decline on July 8 and allegations tied to possible financial manipulation. These are investigations and allegations, not established findings, but they add significant legal and reputational risk. Securities Fraud Investigation Into Alignment Healthcare Continues
• Negative Sentiment: Chief Executive Officer John Kao sold 298,000 shares worth approximately $4.1 million, reducing his direct ownership by 27.37%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, which lessens—but does not eliminate—the negative signaling effect for investors. Alignment Healthcare Insider Trading

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.